ADVERTISEMENT



Google       
Call (866) 635-2689 for a free Personal Injury evaluation by attorney in your area.

Home -> Law Blog Directory -> Personal Injury Law Blogs -> The Personal Injury Lawyer Directory

OR PHONE (866) 635-1838 for Bankruptcy Help, (866) 635-6190 for Divorce,
(866) 635-2689 for Personal Injury or (866) 635-9402 for Criminal Defense

Find a Local Lawyer

Bankruptcy (866) 635-1838
Divorce (866) 635-6190
Personal Injury (866) 635-2689
Criminal Defense (866) 635-9402

Bookmark

Personal Injury Law

: The Personal Injury Lawyer Directory

Makers of Vytorin Withheld Findings

ADVERTISEMENTS

The Senate's Finance Committee and the House's Energy and Commerce Committee allege that the makers of the cholesterol drug, Vytorin, withheld negative findings to boost sales. Drug makers Merck & Co. and Schering-Plough Corp. are accused of suppressing data that shows Vytorin is only as effective as another generic drug called Zocor, made by Merck. The findings were partially released in January due to congressional pressure.

Vytorin combines Zocor and Schering-Plough's Zetia, and was heavily advertised as a new and improved cholesterol fighting drug. This cooperative endeavor brought the companies $5.1 billion in sales in 2007.

Not only does Vytorin cost much more than Zocor, but Sen. Chuck Grassley of Iowa said in a letter that delaying the results affected medical decisions, as well as put financial strain on patients and the government. Hundreds of millions of dollars have been spent by the government since the study ended nearly two years ago. Cardiologists are recommending that doctors go back to older tried-and-true cholesterol fighting drugs.

Two Versions of Why

The government alleges that the two drug companies withheld their poor findings in order to pump up their profits, even though they realized Vytorin was not as powerful as they claimed. Sen. Grassley's letter also cites emails to Schering Plough executives from cardiologist Dr. John Kastelein. Kastelein stated that the suppression of the data was beginning to seem like it was done "for no other reason (than) political reasons."

A spokeswoman for Merck stated that executives did not find out about the findings until after January, and that interpreting the data took longer than expected. Schering-Plough's spokeswoman claims the company "did not deliberately delay" the findings to boost sales.

Stocks of both companies fell sharply after this story was reported on Monday, and has "cast a shadow" over the futures of both companies, though Merck is expected to fare better than Schering-Plough.

If you, or a loved one, have been taking Vytorin in the belief that it is better than the generic version, Zocor, you may have a pharmaceutical claim. Please contact a personal injury lawyer in your area to discuss your situation.

Full post as published by The Personal Injury Lawyer Directory on April 01, 2008 (boomark / email).

Bloggers, promote your law blog by nominating your blog for inclusion in USLaw.com's Law Blog Directory and RSS Reader. Benefits described.
Lawsuits and Settlements

Related Searches

























































































































US Law
#1 Online Legal Resource













Your Blog Subscriptions
Subscribe to blogs

10,000+ Law Job Listings
Lawyer . Police . Paralegal . Etc
Earn a law-related degree
Are you the author of this blog? Adding USLaw.com to your Blogroll increases relevance. You qualify to display a USLaw Network badge.
Suggest changes to this blog's description or nominate another for inclusion. Register for updates.


Practice Area
Zip Code:

Contact a Lawyer Now!






0.0134 secs (new cache)